My Newest “Biotechnology” Play Is…
*** Plandai Biotechnology Inc. (OTCBB: PLPL)***
PLPL (Plandai Biotechnology, Inc.) through its subsidiaries focuses on the farming of whole fruits, vegetables and live plant material and the production of functional foods and botanical extracts for the health and wellness industry.
PLPL principle holdings consist of land, farms and infrastructure in South Africa. The Company has a technology that extracts bio-available compounds from organic matter, including green tea leaves and most other organic materials.
PLPL is the first botanical extraction business in South Africa addressing the issues of unprofitable tea estates by making them viable through the harvesting of fresh green tea leaf for the sole purpose of extracting a bioavailable green tea gallate catechin extract.
PLPL intends to use its plantation leases to focuses on the farming of whole fruits, vegetables and live plant material and the production of functional foods and botanical extracts for the health and wellness industry using its extraction technology.
Top Investor Highlights
- PLPL has projected very strong revenue growth in the short term and has expressed confidence in 2012-2013 revenues exceeding $27,000,000. A further 5-year projection has set revenue targets exceeding $90,000,000. These are all strong signals and will provide investors with solid gain potential
- PLPL is operating in the extremely lucrative green tea market which is in a high growth stage with increasing annual volume growth rates between 13-14%
- PLPL is trading solidly above its SMA50 of 0.20 and also above its SMA20 of 0.33
- PLPL has a RSI of 90.22 but the underlying trends suggests that investors continue to be bullish on the strength that PLPL is hugely undervalued
- PLPL announced extremely positive news that its Phytofare™ Catechin Extract has proven effective in killing the malaria parasite, plasmodium falciparum, in analytical tests
- PLPL brings to market a solid track record having under its belt a solid 10 years of research in the field of plant extracts
--------------------------------------------------------------------------------------------------
PLPL Is Launching Three New Products Branded Under the Phytofare Brand Name
PLPL recently announced its intent to launch three new products all being individually labelled and branded under the Phytofare(TM) name. In addition to the products, the patented extraction process the company will use to bring customers its healthy lineup of extracts will also be highlighted.
The highly bioavailable extract, Phytofare(TM) Catechin Extract (“PCE”), is the first product to gain attention under the launch strategy. PCE is a natural flavonoid rich in phenols and antioxidants. Catechins are chemical compounds essential to boosting the immune system, lowering cholesterol, fighting obesity, and aiding in the prevention of cancers, malaria, and many other parasitic and viral infections.
PLPL has indicated that Phytofare(TM) PCE is a 65 percent polyphenol extract containing 85-88 percent catechins through the release of the active and stable immature catechin precursors from the green tea leaf. Phytonutrients, particularly catechins derived from green tea and its components, have been thoroughly researched (over 200 published scientific papers) and shown to have anti-viral and anti-inflammatory properties.
PLPL has expressed very strong confidence in the upcoming new products, particularly as they relate to the green tea market.
According to PLPL, Most green tea extracts are made from dried unfermented tea leaf -- meaning that the antioxidants have been compromised in stability and activity. However, Phytofare(TM) PCE is recovered from live plant material, retaining the catechins in an active and stable form.
PLPL has signalled that its competitive muscle will be flexed rigorously with the launch of these new products and market share will potentially increase. According to the announcement, Plandai Biotechnology will bring to the market a scientifically improved, more bioavailable line of products. To accomplish this, Plandai will put on its lab coats and employ a patented extraction process that allows this biotech to beat its competition. This process begins with the first product the company will bring to market, Phytofare(TM) Catechin Extract.
-------------------------------------------------------------------
Technical Indicators for PLPL
PLPL looks ready to climb upwards towards its next resistance level of 0.62 in the very near future and recent trading saw volume jump 43.78% above its average!
Recent declines belie the true nature of PLPL, which has continued trading above both its SMA50 and SMA20 in recent trading.
The launch of upcoming new products will bolster PLPL revenues and strengthen the company’s market cap which is currently $53.23m.
The Market Outlook for PLPL Looks Very Lucrative
PLPL is part of an industry that is tipped to grow exponentially in the coming years. In 2010, the botanical and natural ingredient export trade reached approximately $33 bln, according to the Market News Service (MNS) “Medicinal Plant and Extracts” report, published in the MNS December 2011 bulletin. By 2015, the international herb supplement and remedies market is expected to reach $93 bln, according to a report by San Jose, CA-based Global Industry Analysts, Inc.
PLPL is on track to further cement itself in the marketplace and extract sizable revenue growth from an industry which is presently generating composite revenues of $16.8 bln.
PLPL believes that the underlying demands will translate into growth both in terms of revenues and market share. "The dynamic growth of this industry using formulated green tea extracts as alternative medicine or as a synergistic combination therapy with pre-existing antiviral or antibiotics depends on a method of delivery that ensures its stability and greater bioavailability.”
The fight against malaria is a worldwide initiative relying on the ongoing efforts of top biotech companies like PLPL. It’s recent advances with Phytofare™ Catechin Extract which has proven effective in killing the malaria parasite, plasmodium falciparum, is an important step in becoming a go-to source for Malaria treatment.
PLPL has indicated that once its treatment drug for Malaria has gone through the full battery of testing, and results evaluated, a submission will be made to the US Food and Drug Administration for approval to commence Phase II human clinical trials.
PLPL at present valuation is grossly undervalued.
The slew of positive developments means that investors have the potential for unlocking huge gains.
Take care,
Insidebulls
